{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:04:25Z","timestamp":1793037865165,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM22\/00073"],"award-info":[{"award-number":["CM22\/00073"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ctrv.2024.102865","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T12:40:26Z","timestamp":1734612026000},"page":"102865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"132","author":[{"given":"Francesco","family":"Schettini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Nucera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Mart\u00ednez-S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"S\u00e1nchez-Bayona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Buono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Punie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Miguel","family":"Cejalvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Arpino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Vigneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Generali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Ciruelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Gennari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Vidal Losada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Villacampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctrv.2024.102865_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.ctrv.2024.102865_b0010","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35323","article-title":"Characterization of HER2-low breast cancer in young women with germline BRCA1\/2 pathogenetic variants: Results of a large international retrospective cohort study","author":"Schettini","year":"2024","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102865_b0015","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102865_b0020","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.3390\/cancers13112824","article-title":"HER2-Low breast cancer: Molecular characteristics and prognosis","volume":"13","author":"Agostinetto","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102865_b0025","doi-asserted-by":"crossref","first-page":"7496","DOI":"10.1038\/s41467-023-43324-w","article-title":"Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer","volume":"14","author":"Tarantino","year":"2023","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102865_b0030","first-page":"1177","article-title":"Prognostic and biologic significance of ERBB2-Low expression in early-stage breast cancer","volume":"8","author":"Tarantino","year":"2022","journal-title":"JAMA Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2024.102865_b0035","first-page":"00301","article-title":"Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials","volume":"S1470\u20132045","author":"Denkert","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102865_b0040","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12916-022-02284-6","article-title":"HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis","volume":"20","author":"Tan","year":"2022","journal-title":"BMC Med"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102865_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103619","article-title":"Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive\/HER2-low and HER2-0 breast cancer","volume":"9","author":"Schettini","year":"2024","journal-title":"ESMO Open"},{"issue":"17","key":"10.1016\/j.ctrv.2024.102865_b0050","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1200\/JCO.19.02318","article-title":"antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: Results from a phase Ib study","volume":"38","author":"Modi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.ctrv.2024.102865_b0055","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab govitecan in hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10411","key":"10.1016\/j.ctrv.2024.102865_b0060","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.ctrv.2024.102865_b0065","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102865_b0070","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3322\/caac.21705","article-title":"Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2024.102865_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103677","article-title":"Best of the year: Advanced breast cancer in 2023","volume":"74","author":"Schlam","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2024.102865_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102468","article-title":"Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer","volume":"111","author":"Schettini","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2024.102865_b0085","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","author":"Bardia","year":"2024","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ctrv.2024.102865_b0090","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-breast01","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102865_b0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102865_b0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.1003","article-title":"Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor\u2013positive\/HER2-negative (HR+\/HER2\u2013) metastatic breast cancer (mBC)","author":"Tolaney","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102865_b0105","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1016\/j.annonc.2022.03.187","article-title":"168P Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the phase III ASCENT study","volume":"33","author":"Hurvitz","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102865_b0110","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102865_b0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41523-024-00635-5","article-title":"Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"10","author":"Hurvitz","year":"2024","journal-title":"npj Breast Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102865_b0120","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(19)30420-6","article-title":"Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis","volume":"20","author":"Giuliano","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102865_b0125","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/oncolo\/oyad308","article-title":"Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: The DE-REAL study","volume":"29","author":"Botticelli","year":"2023","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102865_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100553","article-title":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer","volume":"7","author":"Rugo","year":"2022","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102865_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"9","author":"Herrstedt","year":"2024","journal-title":"ESMO Open"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2024.102865_b0140","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1200\/JCO.2024.42.16_suppl.1101","article-title":"Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+\/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial","volume":"42","author":"P\u00e9rez Garc\u00eda","year":"2024","journal-title":"JCO"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102865_b0145","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1200\/OP.23.00097","article-title":"Detecting and managing T-DXd-Related interstitial lung disease: The five \u201cS\u201d rules","volume":"19","author":"Tarantino","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102865_b0150","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/HCO.0000000000000637","article-title":"Cardiotoxicity of HER2-targeted therapies","volume":"34","author":"Copeland-Halperin","year":"2019","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.ctrv.2024.102865_b0155","unstructured":"Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial. September 23, 2024. Accessed December 4, 2024. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2024\/datopotamab-deruxtecan-final-overall-survival-results-reported-in-patients-with-metastatic-hr-positive-her2-low-or-negative-breast-cancer-in-tropion-breast01-phase-iii-trial.html."},{"issue":"12","key":"10.1016\/j.ctrv.2024.102865_b0160","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.ctrv.2024.102865_b0165","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1200\/JCO.22.01533","article-title":"Chemotherapy and targeted therapy for human epidermal growth factor receptor 2-negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor-negative: ASCO guideline rapid recommendation update","volume":"40","author":"Moy","year":"2022","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.ctrv.2024.102865_b0170","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.21.01392","article-title":"Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update","volume":"39","author":"Burstein","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102865_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102865_b0180","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1200\/OP.22.00480","article-title":"Real-world perspectives and practices for pneumonitis\/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2-expressing metastatic breast cancer","volume":"19","author":"Rugo","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.ctrv.2024.102865_b0185","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejca.2021.02.035","article-title":"Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis","volume":"149","author":"Schettini","year":"2021","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102865_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102233","article-title":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis","volume":"9","author":"Michelon","year":"2024","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102865_b0195","article-title":"Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update","volume":"41","author":"Burstein","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102865_b0200","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.24.00248","article-title":"Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update","volume":"42","author":"Burstein","year":"2024","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ctrv.2024.102865_b0205","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.ctrv.2024.102865_b0210","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2024.102865_b0215","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231183679","article-title":"Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment","volume":"15","author":"Nader-Marta","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2024.102865_b0220","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1200\/JCO.2023.41.16_suppl.1022","article-title":"Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study","volume":"41","author":"Abelman","year":"2023","journal-title":"JCO"},{"issue":"9_Supplement","key":"10.1016\/j.ctrv.2024.102865_b0225","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PS08-01","article-title":"Abstract PS08-01: Antibody-Drug Conjugates (ADCs) in Breast Cancer: Real World Analysis of Outcomes","volume":"84","author":"Raghavendra","year":"2024","journal-title":"Cancer Res"},{"issue":"9_Supplemen","key":"10.1016\/j.ctrv.2024.102865_b0230","article-title":"Abstract PS08-04: Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)","volume":"84","author":"Huppert","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102865_b0235","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-024-02766-9","article-title":"Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer","author":"Poumeaud","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2024.102865_b0240","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/j.annonc.2022.03.277","article-title":"LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial","volume":"33","author":"Mosele","year":"2022","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102865_b0245","doi-asserted-by":"crossref","first-page":"10211","DOI":"10.3390\/curroncol30120743","article-title":"Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles","volume":"30","author":"Fenton","year":"2023","journal-title":"Curr Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102865_b0250","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab Deruxtecan, a Novel TROP2-directed Antibody\u2013drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102865_b0255","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1158\/2159-8290.CD-22-0837","article-title":"Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis","volume":"12","author":"Jerusalem","year":"2022","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102865_b0260","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","article-title":"Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: A single-arm, phase 2 trial","volume":"28","author":"Bartsch","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2024.102865_b0265","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.1016\/j.annonc.2023.09.565","article-title":"388P Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician\u2019s choice (TPC)","volume":"34","author":"Tsurutani","year":"2023","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102865_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102995","article-title":"The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients-a multicenter real-world analysis","volume":"9","author":"Dannehl","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2024.102865_b0275","first-page":"9","article-title":"187P Stage I results of a phase II study of datopotamab deruxtecan (DATO-DXd) in triple-negative breast cancer (TNBC) patients (pts) with active brain metastases (TUXEDO-2)","author":"Bartsch","year":"2024","journal-title":"ESMO Open"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T03:26:27Z","timestamp":1736479587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737224001944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":55,"alternative-id":["S0305737224001944"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102865","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102865","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102865"}}